![](https://ml.globenewswire.com/media/7af5aa20-16b6-4c17-af80-fa564e72633f/small/onco360-hor-png.png)
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult ...
LOUISVILLE, Ky., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE™ (lazertinib). LAZCLUZE™ is a third-generation epidermal growth …